Interferon-alpha protects mice against lethal infection with St Louis encephalitis virus delivered by the aerosol and subcutaneous routes.
In common with other flaviviruses, there is no specific therapy for St Louis encephalitis (SLE) virus infections. A number of cases have occurred where infection may have been acquired by the aerosol route in laboratory accidents. The recombinant human interferon hybrids IFN-alpha A/D (Roche Laboratories) and IFN-alpha B/D (Ciba-Geigy) have activity in murine models. Given for several days around the time of exposure to the virus or shortly after, these compounds reduce the mortality from SLE virus administered to mice subcutaneously by up to 70%. In an aerosol model of SLE disease, the mortality was reduced to 30-50% compared to 100% in controls, depending on the challenge level of virus. These results suggest that interferon-alpha could be used to reduce the mortality from SLE infection after known exposure to the virus.
D000818:Animals; D001921:Brain / Q000473:pathology / Q000821:virology; D004665:Encephalitis Virus, St. Louis / Q000302:isolation & purification; D004674:Encephalitis, St. Louis / Q000188:drug therapy / Q000473:pathology / Q000517:prevention & control* / Q000821:virology; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use*; D016898:Interferon-alpha; D051379:Mice; D008807:Mice, Inbred BALB C; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D011994:Recombinant Proteins